Geron Corporation (GERN) Releases Earnings Results, Misses Expectations By $-0.01 EPS

Geron Corporation (GERN) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.06 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $-0.05. The company posted revenue of $.74 million in the period, compared to analysts expectations of $.26 million. The company’s revenue was up 37.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.

Geron Corporation closed down -0.11 points or -3.87% at $2.73 with 31,43,301 shares getting traded on Wednesday. Post opening the session at $2.83, the shares hit an intraday low of $2.69 and an intraday high of $2.85 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Jun 1, 2015, Olivia Kyusuk Bloom (EVP, Chief Financial Officer) sold 2,380 shares at $3.84 per share price. According to the SEC, on Jun 1, 2015, Melissa Kelly Behrs (EVP BD and Port&Alliance Mgmt) sold 2,380 shares at $3.84 per share price. On Mar 19, 2015, Thomas Hofstaetter (director) sold 70,000 shares at $4.10 per share price, according to the Form-4 filing with the securities and exchange commission.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor imetelstat in hematologic myeloid malignancies. The Company operates in one segment the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells including malignant progenitor cells to maintain telomere length which provides a capacity for limitless uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR) which binds to the telomere and a catalytic subunit (hTERT) with reverse transcriptase activity which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Geron Corporation

Leave a Reply

Geron Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Geron Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.